Massachusetts Financial Services
CTMX icon

Massachusetts Financial Services’s CytomX Therapeutics CTMX Stock Holding History

Massachusetts Financial Services’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-357,134
Closed -$1.55M – 870
2021
Q4 		$1.55M Sell
357,134
-31,186
-8% -$183K ﹤0.01% 794
2021
Q3 		$1.98M Buy
388,320
+92,602
+31% +$496K ﹤0.01% 785
2021
Q2 		$1.87M Buy
295,718
+2,535
+0.9% +$19.7K ﹤0.01% 788
2021
Q1 		$2.27M Buy
293,183
+37,218
+15% +$295K ﹤0.01% 756
2020
Q4 		$1.68M Sell
255,965
-2,570
-1% -$18.4K ﹤0.01% 754
2020
Q3 		$1.72M Buy
258,535
+54,800
+27% +$406K ﹤0.01% 733
2020
Q2 		$1.7M Sell
203,735
-5,190
-2% -$48.2K ﹤0.01% 701
2020
Q1 		$1.6M Buy
208,925
+33,069
+19% +$231K ﹤0.01% 701
2019
Q4 		$1.46M Sell
175,856
-19,006
-10% -$128K ﹤0.01% 740
2019
Q3 		$1.44M Buy
+194,862
New +$1.92M ﹤0.01% 754

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Massachusetts Financial Services's CTMX Position: Q1 2022 in Review

Massachusetts Financial Services sold out of CytomX Therapeutics (CTMX) in Q1 2022, closing a stake of 357,134 shares — an estimated $1.55M sold.

Massachusetts Financial Services first reported a position in CTMX in Q3 2019 and held it in 10 quarters. The position peaked at $2.27M in Q1 2021. 119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

  • Massachusetts Financial Services reported no remaining CytomX Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Massachusetts Financial Services sold 357,134 CytomX Therapeutics shares in Q1 2022, an estimated $1.55M.
  • Massachusetts Financial Services first reported a position in CytomX Therapeutics in Q3 2019 and held it in 10 quarters.
  • Massachusetts Financial Services's CytomX Therapeutics position peaked at $2.27M in Q1 2021.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Massachusetts Financial Services's 13F filing for Q1 2022, filed 11 May 2022.